For the Inventor, By the Inventor

Enter assignee name

Dunedin, New Zealand

Pacific Edge Limited

Calculating rank

USPTO Granted Patents = 16

% Expired Patents = 56.3

EPO Patents = 13

Trademarks = 3

Forward Citations = 33

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Parry John Guilford (13 out of 14 patents)

Michael Alan Black (5 out of 5 patents)

Mark Dalphin (3 out of 3 patents)

4. Laimonis Kavalieris (3 out of 3 patents)

5. Paul O'Sullivan (3 out of 3 patents)

6. Robert Craig Pollock (3 out of 3 patents)

7. Jonathan Cebon (3 out of 5 patents)

8. Thomas John (3 out of 4 patents)

9. Hjalmar Nekarda (2 out of 2 patents)

10. Jan Friederichs (2 out of 2 patents)

11. Bernhard Holzmann (2 out of 2 patents)

12. Robert Rosenberg (2 out of 2 patents)

13. Anthony Edmund Reeve (2 out of 3 patents)

14. John Lindsay McCall (2 out of 2 patents)

15. Yu-Hsin Lin (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 11208698 - Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof (2021-12-28),

2. 11180815 - Methods for treating colorectal cancer using prognostic genetic markers (2021-11-23),

3. 11130789 - Urine markers for detection of bladder cancer (2021-09-28),

4. 10689711 - Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof (2020-06-23),

5. 10689707 - Treatment of recurrent gastric cancer identified using genetic biomarkers (2020-06-23),

6. 10422005 - Methods for treating colorectal cancer using prognostic genetic markers (2019-09-24),

7. 10266902 - Methods for prognosis prediction for melanoma cancer (2019-04-23),

8. 10179935 - Markers for detection of gastric cancer (2019-01-15),

9. 10131955 - Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof (2018-11-20),

10. 10024859 - Markers for detection of gastric cancer (2018-07-17),

11. 9982305 - Polymerase chain reaction test kits for detecting markers of bladder cancer (2018-05-29),

12. 9809860 - Test kits and methods for their use in detecting expression ratios of genetic markers (2017-11-07),

13. 9702009 - Urine gene expression ratios for detection of cancer (2017-07-11),

14. 9534258 - Devices and methods for prognosis prediction for melanoma cancer (2017-01-03),

15. 9310370 - Markers for detection of gastric cancer (2016-04-12),

Company Overview

Pacific Edge Limited is a biotechnology company based in Dunedin, New Zealand, specializing in the development of innovative diagnostic solutions for cancer management. The company focuses on creating non-invasive tests that aid in the detection and monitoring of various cancers, leveraging advanced molecular biology techniques. With a commitment to improving patient outcomes, Pacific Edge is at the forefront of transforming cancer care through its proprietary technologies and research initiatives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

16 Patents

#2 in Dunedin

#43 in New Zealand

#37,887 in the World

Dunedin, New Zealand

Pacific Edge Limited

Forward Citations = 33

20 inventors:

Parry John Guilford (13 out of 14 patents)

Michael Alan Black (5 out of 5 patents)

Mark Dalphin (3 out of 3 patents)

4. Laimonis Kavalieris (3 out of 3 patents)

5. Paul O'Sullivan (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pacific Edge Limited. Retrieved from https://idiyas.com/company/pacific-edge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…